| 1 |
Phase 1 Clinical Development to Evaluate the Safety and Efficacy of IPS101A Gene Therapy Product for Severe Parkinson's Disease |
| Gene & Nucleic acids |
Parkinson's Disease |
Nurr1, Foxa2 |
Phase 1 |
Innopeutics Corporation |
RS-2026-25501504 |
|
| 2 |
IM-101: anti-C5 monoclonal antibody for myasthenia gravis |
| Antibody |
Myasthenia Gravis |
Human Complement 5(C5) |
Phase 1 |
ImmunAbs, Inc. |
RS-2025-25454824 |
|
| 3 |
Phase 1 Clinical Development of Cerium Oxide-Based Nanozyme CX213 for the Treatment of Subarachnoid Hemorrhage as an Orphan Drug |
| Others-Synth. |
SAH |
활성산소(ROS) |
Phase 1 |
Cenyx Biotech Inc. |
RS-2025-02183050 |
|
| 4 |
Evaluating the safety and efficacy of PRG-N-01 in patients with Neurofibromatosis Type 2 |
| Small molecules |
Neurofibromatosis Type 2 |
Oncopathogenic neo-TβR1-RKIP interaction |
Phase 1 |
PRG S＆Tech Inc. |
RS-2024-00442484 |
|
| 5 |
Development of a novel c.Abl and LRRK2 dual inhibitor for Parkinson’s Disease Treatment |
| Small molecules |
Parkinson's disease |
c.Abl/LRRK2 |
Phase 1 |
1ST Biotherapeutics Inc. |
RS-2023-00283009 |
|